Canopy Immuno-Therapeutics
Immunotherapeutic Approach for Autoimmunity and Life-threatening Allergies
StartupCanopy Immuno-Therapeutics is a Haifa-based startup in the Health Tech & Life Sciences sector, established in 2020. Immunotherapeutic Approach for Autoimmunity and Life-threatening Allergies. Canopy Immuno-Therapeutics was founded by Kfir Oved. Key investors include TLV Partners. The company has 1-10 employees. Core technologies: Platforms & Interfaces, Software, Artificial Intelligence.
The company follows a B2B business model. Product stage: R&D.
- StageA
- ProductR&D
- ModelB2B
- Employees1-10
- HQHaifa
- DistrictNorth District
- Last RoundUndisclosed
- TLV Partners
Kfir OvedFounder & CEO
1 article covered by sources including www.thelancet.com.
What does Canopy Immuno-Therapeutics do?
Canopy is a pre-clinical stage biotech developing a new class of biologics that will allow the elimination of antigen-specific immunity, providing non-immunosuppressive, potentially curing treatments to many dozens of autoimmune, allergic, and other antibody-mediated conditions using its proprietary Reverse-Immunization platform.
Who founded Canopy Immuno-Therapeutics?
Canopy Immuno-Therapeutics was founded in 2020 by Kfir Oved (Founder & CEO).
What sector is Canopy Immuno-Therapeutics in?
Canopy Immuno-Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Platforms & Interfaces, Software, Artificial Intelligence. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology.
Where is Canopy Immuno-Therapeutics located?
Canopy Immuno-Therapeutics is based in Haifa, Israel, North District.